CorMedix Statistics
Share Statistics
CorMedix has 60.68M shares outstanding. The number of shares has increased by 10.7% in one year.
| Shares Outstanding | 60.68M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 8.62% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 59.77M |
| Failed to Deliver (FTD) Shares | 97.20K |
| FTD / Avg. Volume | 8.29% |
Short Selling Information
The latest short interest is 6.73M, so 11.09% of the outstanding shares have been sold short.
| Short Interest | 6.73M |
| Short % of Shares Out | 11.09% |
| Short % of Float | 11.26% |
| Short Ratio (days to cover) | 7.22 |
Valuation Ratios
The PE ratio is -4.13 and the forward PE ratio is 24.31.
| PE Ratio | -4.13 |
| Forward PE | 24.31 |
| PS Ratio | 0 |
| Forward PS | 2.9 |
| PB Ratio | 2.73 |
| P/FCF Ratio | -4.94 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for CorMedix Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.97, with a Debt / Equity ratio of 0.
| Current Ratio | 6.97 |
| Quick Ratio | 6.78 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.66% and return on capital (ROIC) is -69.14%.
| Return on Equity (ROE) | -0.66% |
| Return on Assets (ROA) | -0.56% |
| Return on Capital (ROIC) | -69.14% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -565.11K |
| Employee Count | 82 |
| Asset Turnover | 0 |
| Inventory Turnover | 0.1 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 141% in the last 52 weeks. The beta is 1.58, so CorMedix 's price volatility has been higher than the market average.
| Beta | 1.58 |
| 52-Week Price Change | 141% |
| 50-Day Moving Average | 9.96 |
| 200-Day Moving Average | 6.75 |
| Relative Strength Index (RSI) | 38.18 |
| Average Volume (20 Days) | 1.17M |
Income Statement
| Revenue | n/a |
| Gross Profit | -205.56K |
| Operating Income | -48.96M |
| Net Income | -46.34M |
| EBITDA | -48.89M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.91 |
Balance Sheet
The company has 43.64M in cash and 667.63K in debt, giving a net cash position of 42.98M.
| Cash & Cash Equivalents | 43.64M |
| Total Debt | 667.63K |
| Net Cash | 42.98M |
| Retained Earnings | -321.70M |
| Total Assets | 77.59M |
| Working Capital | 54.67M |
Cash Flow
In the last 12 months, operating cash flow was -38.41M and capital expenditures -327.30K, giving a free cash flow of -38.74M.
| Operating Cash Flow | -38.41M |
| Capital Expenditures | -327.30K |
| Free Cash Flow | -38.74M |
| FCF Per Share | -0.76 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -11.14% |
| FCF Yield | -7.81% |
Analyst Forecast
The average price target for CRMD is $17, which is 108.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $17 |
| Price Target Difference | 108.1% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Mar 26, 2019. It was a backward split with a ratio of 1:5.
| Last Split Date | Mar 26, 2019 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | 8.68 |
| Piotroski F-Score | 2 |